Information Provided By: 
Fly News Breaks for November 25, 2015
PFE
Nov 25, 2015 | 07:44 EDT
SunTrust upgraded Pfizer (PFE) to Neutral and increased its price target to $37 from $34 on shares. Analyst John Boris said the Allergan (AGN) deal makes strategic sense, providing much needed growth from earlier life cycle assets with limited therapeutic overlap.
News For PFE From the Last 2 Days
PFE
Apr 22, 2024 | 08:13 EDT
Pfizer announced that the European Commission, or EC, has granted marketing authorization for Emblaveo for the treatment of adult patients with complicated intra-abdominal infections, or cIAI, hospital-acquired pneumonia, or HAP, including ventilator-associated pneumonia, or VAP, and complicated urinary tract infections, or cUTI, including pyelonephritis. It is also indicated for the treatment of infections due to aerobic Gram-negative organisms in adult patients with limited treatment options.
